Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

fter, and follow any dose adjustments. - Sudden deaths have been reported in patients receiving nilotinib. Do not administer TASIGNA to patients with hypokalemia, hypomagnesemia, or long QT syndrome. - Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors.- Patients should avoid food 2 hours before and 1 hour after taking dose.
  • Treatment with TASIGNA can cause Grade 3/4 thrombocytopenia, neutropenia, and anemia. Complete blood counts should be performed every 2 weeks for the first 2 months and then monthly thereafter.
  • Caution is recommended in patients with a history of pancreatitis.
  • The use of TASIGNA may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase.
  • TASIGNA can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia (see Boxed WARNING).
  • The concomitant use of strong CYP3A4 inhibitors or anti-arrhythmic drugs (including, but not limited to, amiodarone, disopyramide, procainamide, quinidine, and sotalol) and other drugs that may prolong the QT interval (including, but not limited to, chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, and pimozide) should be avoided. Grapefruit products should also be avoided. 
  • The concomitant use of strong CYP3A4 inducers should be avoided (including, but not limited to, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St. John's wort).
  • TASIGNA must not be taken with food.
  • TASIGNA exposure is increased in patients with impaired hepatic function.
  • Cases of tumor lysis syndrome have been reported in TASIGNA treated patients with resistant or intolerant CML. Due to potential for tumor lysis syndrome, maintain adequate hydration and correct uric acid levels prior to initiating therapy with TASIGNA.
  • The exposure of TASIGNA is reduced in patients with total gastrectomy.
  • Since the capsules contain lactose, TASIGNA is not recommended for p
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related biology technology :

    1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
    2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
    3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
    4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
    5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
    6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
    7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
    8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
    9. Novartis Class Awarded $250 Million in Punitive Damages
    10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
    11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
    (Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
    (Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
    (Date:8/28/2014)... Aug. 28, 2014 ... market research report is available ... Whole Exome Sequencing Market by ... Target Enrichment), by Services (Sequencing), ... by Application (Cancer, Monogenic disorders) ...
    Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
    ... leading nonprofit organizations - the American Botanical Council ... University of Mississippi,s National Center for Natural Products ... to educate members of the herbal and dietary ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) ...
    ... SAN FRANCISCO, Nov. 2, 2011 Jennerex, Inc., a ... commercialization of first-in-class targeted oncolytic products for cancer, today ... clinical trial in advanced liver cancer patients will be ... Annual Meeting of the American Association for the Study ...
    ... 2, 2011 - Vaginal Self-collection for ... Increases Screening Coverage and is More Sensitive than Pap Smear ... Promising findings published today online in the ... trial undertaken by public health authorities in Mexico to investigate ...
    Cached Biology Technology:Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 2Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 3Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 4Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 5Nonprofit Collaboration Addresses Adulteration of Botanical Dietary Ingredients 6Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 2Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 3Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 4Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 2Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 3Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 4Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 5
    (Date:8/29/2014)... In a cell,s nucleus, chromosomal DNA is tightly ... amalgam biologists call chromatin. Until about two decades ... the mere packing material around which the glamorous ... developed a greater appreciation for how DNA/histone interactions ... multiple research institutions studying the sequence of the ...
    (Date:8/29/2014)... The rise of the Tibetan plateau -- the largest ... important for both its profound effect on climate and ... in GSA Bulletin , Katharine Huntington and colleagues ... -- using modern and fossil snail shells to investigate ... Tibet. , Views range widely on the timing ...
    (Date:8/28/2014)... Society of America (ESA) is pleased to announce the ... of the Society. Honorary Membership acknowledges those who have ... involvement in the affairs of the Society that has ... selected by the ESA Governing Board and then voted ... honored at the Awards Ceremony at Entomology 2014, ESA,s ...
    Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
    ... In experiments with mice, researchers have found that eliminating ... the development of pain-sensing neurons knocks out the animals' ... that outlasts the injury and is associated with nerve ... in the gene, called Runx1, also showed lack of ...
    ... from Scripps Research; the Genomics Research Center, Academia Sinica, ... published today in the journal Chemistry and Biology (Vol. ... Ernest W. Hahn Chair in Chemistry at the Skaggs ... lab heading the study. He said the new finding ...
    ... Pacific Islands nation has distinguished itself on the global ... creating the third largest marine protected area in the ... most pristine coral reefs. , Martin Puta Tofinga, Minister ... of Kiribati, announced the establishment of the Phoenix Islands ...
    Cached Biology News:Master genetic switch found for chronic pain 2Enzyme inhibitors block replication of SARS virus 2Pacific Islands paradise protected 2Pacific Islands paradise protected 3
    ... single use spatulas have been designed to ... are for those interested in eliminating the ... Each spatula is individually packaged, RNase/DNase free, ... is a new product number, created to ...
    ... of cells • Blade design minimizes cell ... growth surface • Designed for use in ... • Sterilized by gamma radiation and certified ... new product number, created to easily match ...
    ... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
    ... The MagneGST™ Protein Purification System provides ... for the purification of glutathione-S-transferase (GST) ... (MagneGST™ Particles) are used to isolate ... or cleared lysate using either a ...
    Biology Products: